Fear of contracting or spreading COVID-19 might be increasing the severity of these symptoms, notes Dr. Cynthia Rogers.
The Food and Drug Administration has approved a variant of the anesthetic and party drug ketamine for suicidal patients with major depression.
Joan Luby, MD, director of the School of Medicine’s Early Emotional Development Program and the Samuel and Mae S. Ludwig Professor of Child Psychiatry, will receive the Carl and Gerty Cori Faculty Achievement Award. Douglas F. Covey, the Andrew C. and Barbara B. Taylor Distinguished Professor of Psychiatry at the School of Medicine, will receive […]
Researchers in St. Louis have launched a study into whether a long-used antidepressant can reduce the likelihood that COVID-19 will turn deadly.
Researchers at Washington University School of Medicine are recruiting COVID-19 patients for a clinical trial that will examine whether an existing anti-depressant can be an effective treatment for COVID-19.
Washington University in St. Louis will begin construction in March on what will be one of the largest neuroscience research buildings in the country.
Neuroactive steroid drugs result from Taylor Family Institute, pharma collaboration
Professorship supports research in new treatment strategies for psychiatric illness
Glowinski, artist Outlaw address mental health through artwork.
Adam Kepecs, PhD, recognized internationally for his research on neural circuits responsible for cognition and decision-making, has been named a BJC Investigator and a professor of neuroscience and psychiatry at Washington University School of Medicine in St. Louis.
Philanthropists Andrew and Barbara Taylor and the Crawford Taylor Foundation have committed $10 million to Washington University School of Medicine in St. Louis to continue research to investigate the scientific underpinnings of psychiatric illnesses, with the goal of improving diagnosis and treatment.
"The Taylor Family Institute for Innovative Psychiatric Research is pleased to announce the installment of Dr. Doug Covey as the inaugural Taylor Family Distinguished Professor of Psychiatry. Doug's medicinal chemistry work resulted in his co-founding of Sage Therapeutics, which recently brought brexanolone to market as the first drug to treat post-partum depression."